Immunome Reports Third Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire • 11/09/26
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should KnowZacks Investment Research • 11/04/26
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026Business Wire • 11/04/26
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation ConferenceBusiness Wire • 11/02/26
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsBusiness Wire • 10/30/26
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026Business Wire • 10/26/26
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid TumorsBusiness Wire • 09/30/26
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness Wire • 09/02/26
Immunome Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire • 08/11/26
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid TumorsBusiness Wire • 07/20/26
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid TumorsBusiness Wire • 07/08/26
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid TumorsBusiness Wire • 06/11/26
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual MeetingBusiness Wire • 05/30/26
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 05/27/26